Key Points
- Director Kristina Leslie sold 1,250 Hinge Health shares on Nov. 21 at an average price of $45.68 for $57,100, reducing her stake by 4.31% to 27,750 shares, as disclosed in an SEC Form 4.
- Hinge Health beat Q3 estimates, reporting ($0.02) EPS versus a ($0.20) consensus and revenue of $154.21 million, up 53.3% year‑over‑year.
- The company’s Board authorized a $250 million share buyback (up to 7.2% of shares), and analysts hold a consensus "Moderate Buy" rating with an average target price of $59.93.
Hinge Health Inc. (NYSE:HNGE - Get Free Report) Director Kristina Leslie sold 1,250 shares of Hinge Health stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $45.68, for a total value of $57,100.00. Following the transaction, the director owned 27,750 shares in the company, valued at $1,267,620. This trade represents a 4.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Hinge Health Price Performance
NYSE HNGE opened at $47.07 on Tuesday. The business's 50 day simple moving average is $49.47. Hinge Health Inc. has a 52-week low of $33.42 and a 52-week high of $62.18.
Hinge Health (NYSE:HNGE - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.18. The company had revenue of $154.21 million during the quarter, compared to analyst estimates of $142.44 million. The company's revenue was up 53.3% compared to the same quarter last year. Hinge Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS.
Hinge Health declared that its Board of Directors has authorized a share buyback program on Wednesday, November 12th that authorizes the company to repurchase $250.00 million in shares. This repurchase authorization authorizes the company to purchase up to 7.2% of its shares through open market purchases. Shares repurchase programs are often an indication that the company's management believes its shares are undervalued.
Wall Street Analyst Weigh In
Several research firms have issued reports on HNGE. Piper Sandler reissued an "overweight" rating and issued a $71.00 price target (up previously from $70.00) on shares of Hinge Health in a research note on Wednesday, November 5th. Bank of America lifted their target price on Hinge Health from $42.00 to $64.00 and gave the company a "buy" rating in a research report on Wednesday, August 6th. Barclays upped their price target on Hinge Health from $62.00 to $65.00 and gave the stock an "overweight" rating in a research report on Wednesday, November 5th. JMP Securities raised their price target on shares of Hinge Health from $58.00 to $65.00 and gave the stock a "market outperform" rating in a research note on Wednesday, August 6th. Finally, Stifel Nicolaus boosted their price objective on shares of Hinge Health from $63.00 to $66.00 and gave the stock a "buy" rating in a research report on Thursday, September 11th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $59.93.
Get Our Latest Analysis on Hinge Health
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of HNGE. CHURCHILL MANAGEMENT Corp acquired a new position in shares of Hinge Health during the 2nd quarter worth approximately $828,000. FNY Investment Advisers LLC acquired a new position in Hinge Health during the second quarter worth $310,000. Strategic Blueprint LLC bought a new stake in Hinge Health during the second quarter worth $346,000. Emerald Advisers LLC acquired a new stake in Hinge Health in the second quarter valued at $108,000. Finally, Mark Sheptoff Financial Planning LLC acquired a new stake in Hinge Health in the second quarter valued at $114,000.
Hinge Health Company Profile
(
Get Free Report)
Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
